Allspring Global Investments
RUBY

Allspring Global Investments’s Rubius Therapeutics, Inc RUBY Stock Holding History

Allspring Global Investments’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-41,980
Closed -$231K – 3039
2022
Q1 		$231K Sell
41,980
-2,935
-7% -$18.6K ﹤0.01% 2528
2021
Q4 		$434K Buy
+44,915
New +$623K ﹤0.01% 2353

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Allspring Global Investments's RUBY Position: Q2 2022 in Review

Allspring Global Investments sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 41,980 shares — an estimated $231K sold.

Allspring Global Investments first reported a position in RUBY in Q4 2021 and held it in 2 quarters. The position peaked at $434K in Q4 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

  • Allspring Global Investments reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
  • Allspring Global Investments sold 41,980 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $231K.
  • Allspring Global Investments first reported a position in Rubius Therapeutics, Inc in Q4 2021 and held it in 2 quarters.
  • Allspring Global Investments's Rubius Therapeutics, Inc position peaked at $434K in Q4 2021.
  • 72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.